检索结果-南通市图书馆

Virtual patient education for hypertension: The truth about behavioral change

World Journal of Cardiology 2023年第6期15卷 324-327页

作者： zeynep yukselen Yuvaraj Singh Sarat Malempati Mahati Dasari Pramukh Arun Kumar Eddison Ramsaran Department of Internal Medicine Saint Vincent HospitalWorcesterMA 01608United States School of Public Health and Health Sciences University of MassachusettsAmherstMA 01003United States Department of Cardiovascular Medicine Saint Vincent HospitalWorcesterMA 01608United States

Anti-hypertensive education is an important public health intervention to decrease the mortality and burden of the *** digital technologies for education as a part of preventive measures for hypertension is a cost-effective approach and helps low-income communities and vulnerable populations overcome barriers to healthcare *** coronavirus disease 19 pandemic further highlighted the need of new health interventions to address health *** education is helpful to improve awareness,knowledge,and attitude toward ***,given the complexity of behavioral change,educational approaches do not always provide a change in *** of the obstacles in online hypertensive education could be time limitations,not being tailored to individual needs and not including the different elements of behavioral models to enhance behavior *** regarding virtual education should be encouraged and involve lifestyle modifications emphasizing the importance of Dietary Approaches to Stop Hypertension diet,salt restriction,and exercise and should be used adjunct to in-person visits for the management of ***,to stratify patients according to hypertension type(essential or secondary)would be useful to create specific educational *** hypertension education is promising to increase awareness regarding risk factors and most importantly motivate patients to be more compliant with management helping to decrease hypertension related complications and hospitalizations.

关键词： Hypertension Virtual education Health promotion Public health Patient education Patient adherence Dietary approaches to stop hypertension diet

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma:A systematic review

引用

World Journal of Gastrointestinal Oncology 2021年第11期13卷 1813-1832页

作者： Faiza Ahmed Jennifer Onwumeh-Okwundu zeynep yukselen Maria-Kassandra Endaya Coronel Madiha Zaidi Prathima Guntipalli Vamsi Garimella Sravya Gudapati Marc Darlene Mezidor Kim Andrews Mohamad Mouchli Endrit Shahini Division of Clinical and Translational Research Larkin Community HospitalSouth MiamiFL 33143United States Community Health Division University of StellenboschStellenbosch 7602South Africa College of Medicine Howard UniversityWashingtonDC 520United States College of Medicine Washington University of Health and ScienceSan PedroBelize Department of Radiology Amita Health Saint Francis HospitalEvastonIL 60202United States Department of Mathematics and Natural Sciences Prince Mohammad Bin Fahad UniversityAl Khobar 31952Saudi Arabia Department of Gastroenterology Cleveland ClinicClevelandOH 44195United States National Institute of Gastroenterology"S.de Bellis" Research HospitalCastellana Grotte(Bari)70013Italy

BACKGROUND Despite the use of current standard therapy,the prognosis of patients with unresectable hepatocellular carcinoma(HCC)is poor,with median survival times of 40 mo for intermediate HCC(Barcelona Clinic Liver Cancer[BCLC]stage B)and 6-8 mo for advanced HCC(BCLC stage C).Although patients with earlystage HCC are usually suitable for therapies with curative intention,up to 70% of patients experience relapse within 5 *** the past decade,the United States Food and Drug Administration has approved different immunogenic treatment options for advanced HCC,the most common type of liver cancer among ***,no treatment is useful in the adjuvant *** 2007,the multikinase inhibitor sorafenib has been used as a first-line targeted drug to address the increased mortality and incidence rates of ***,in 2020,the IMbrave150 trial demonstrated that combination therapy of atezolizumab(antiprogrammed death-ligand 1[PD-L1])and bevacizumab(anti-vascular endothelial growth factor[VEGF])is superior to sorafenib,a single anti-programmed death 1/PD-L1 antibody inhibitor used as an anti-cancer monotherapy for HCC *** To conduct a systematic literature review to evaluate the evidence supporting the efficacy and safety of atezolizumab/bevacizumab as preferred first-line drug therapy over the conventional sorafenib or atezolizumab monotherapies,which are used to improve survival outcomes and reduce disease progression in patients with unresectable HCC and non-decompensated liver *** A comprehensive literature review was conducted using the PubMed,Scopus,ScienceDirect,***,PubMed Central,Embase,EuropePMC,and CINAHL databases to identify studies that met the inclusion criteria using relevant MeSH *** systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and risk of bias(RoB)were assessed using the Cochrane RoB 2 tool and *** In the

关键词： Hepatic malignancy Combination systemic therapy Immunogenetic therapy Liver transplantation Barcelona clinic liver cancer Transarterial chemoembolization

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：